Review

anti tslp (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems anti tslp
Anti Tslp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 90 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+tslp+biotin+antibody/TSLP+Antibody+%5BBiotin%5D/pmc05036938-230-8-9
Average 94 stars, based on 90 article reviews

anti tslp - by Bioz Stars, 2026-11

94/100 stars

Images

Incubation:

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice
Article Snippet: Protein concentration was determined by a BCA Protein Assay Kit (Pierce). .. Membranes were sequentially blocked in TBST containing 5% skim milk and then incubated with anti‐TSLP‐biotin antibody (1:1000; R&D Systems) and anti‐β‐actin (1:1000; Abcam) at 4°C overnight. .. Membranes were sequentially blocked in TBST containing 5% skim milk and then incubated with anti‐TSLP‐biotin antibody (1:1000; R&D Systems) and anti‐β‐actin (1:1000; Abcam) at 4°C overnight.

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice
Article Snippet: .. Membranes were sequentially blocked in TBST containing 5% skim milk and then incubated with anti-TSLP-biotin antibody (1:1000; R&D Systems) and anti-b-actin (1:1000; Abcam) at 4°C overnight. ..

Recombinant:

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice
Article Snippet: GM‐CSF (lot no. 050755‐1), IL‐4 (lot no. 1106CY49), and IL‐2 (lot no. 0608108) were obtained from Peprotech (Rocky Hill, NJ). .. Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems. .. Purified anti‐CD4 antibody (clone RM4‐5) was from BD Systems (Franklin).

Image Search Results

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Real‐Time RT‐PCR Primer Sequences

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Quantitative RT-PCR, Sequencing

Expression of TSLP on cardiovascular tissue. A and D, Representative images of TSLP staining in the heart and the aorta. B and E, Quantitative PCR analysis of TSLP gene expression in the heart and the aorta (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.0915, ** P =0.0013). C and F, Representative images and intensity analysis of Western blot for the levels of cardiac (*** P =0.0007) and aorta TSLP protein (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.9999; ** P =0.0022) from each treatment. Data are shown as the average±SD of 3 to 6 independent experiments. Black bar=100 μm. **** P <0.0001. ND indicates normal diet; PCR, polymerase chain reaction; SD, standard deviation; TSLP, thymic stromal lymphopoietin; WTD, Western‐type diet.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Expression of TSLP on cardiovascular tissue. A and D, Representative images of TSLP staining in the heart and the aorta. B and E, Quantitative PCR analysis of TSLP gene expression in the heart and the aorta (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.0915, ** P =0.0013). C and F, Representative images and intensity analysis of Western blot for the levels of cardiac (*** P =0.0007) and aorta TSLP protein (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.9999; ** P =0.0022) from each treatment. Data are shown as the average±SD of 3 to 6 independent experiments. Black bar=100 μm. **** P <0.0001. ND indicates normal diet; PCR, polymerase chain reaction; SD, standard deviation; TSLP, thymic stromal lymphopoietin; WTD, Western‐type diet.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Expressing, Staining, Real-time Polymerase Chain Reaction, Gene Expression, Western Blot, Polymerase Chain Reaction, Standard Deviation

Characterization of TSLP‐DCs. A, After being cultured for 2 days under different conditions, BM‐DCs (2×10 5 cells/well) were stained with specific antibodies against CD86 and PD‐L1 and analyzed by FACS. B, Mean fluorescence intensities (MFIs) for CD86 (* P =0.0156, *** P =0.0002) and PD‐L1 (** P =0.0030 for both) were quantified. C, Quantitative PCR analysis of IL‐12 (*** P =0.0003) and TGF‐β (* P =0.0135; *** P =0.0008) for the DCs in different groups. D, Quantification of IL‐12 by ELISA in the supernatants of each group ( # P =0.5435). E, Quantification of TGF‐β by ELISA (*** P =0.0002). Data are shown as the average±SD of 3 to 5 independent experiments. **** P <0.0001. BM indicates bone marrow; DCs, dendritic cells; ELISA, enzyme‐linked immuno sorbent assay; FACS, fluorescence‐activated cell sorting; IL, interleukin; oxLDL, oxidized low‐density lipoprotein; PCR, polymerase chain reaction; PD‐L1, programmed death ligand 1; SD, standard deviation; TGF‐β, transforming growth factor‐β; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Characterization of TSLP‐DCs. A, After being cultured for 2 days under different conditions, BM‐DCs (2×10 5 cells/well) were stained with specific antibodies against CD86 and PD‐L1 and analyzed by FACS. B, Mean fluorescence intensities (MFIs) for CD86 (* P =0.0156, *** P =0.0002) and PD‐L1 (** P =0.0030 for both) were quantified. C, Quantitative PCR analysis of IL‐12 (*** P =0.0003) and TGF‐β (* P =0.0135; *** P =0.0008) for the DCs in different groups. D, Quantification of IL‐12 by ELISA in the supernatants of each group ( # P =0.5435). E, Quantification of TGF‐β by ELISA (*** P =0.0002). Data are shown as the average±SD of 3 to 5 independent experiments. **** P <0.0001. BM indicates bone marrow; DCs, dendritic cells; ELISA, enzyme‐linked immuno sorbent assay; FACS, fluorescence‐activated cell sorting; IL, interleukin; oxLDL, oxidized low‐density lipoprotein; PCR, polymerase chain reaction; PD‐L1, programmed death ligand 1; SD, standard deviation; TGF‐β, transforming growth factor‐β; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Cell Culture, Staining, Fluorescence, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, FACS, Polymerase Chain Reaction, Standard Deviation

Coculture of BM‐DCs and T cells. A, Representative FACS analysis of the percentages of nTregs and CD4 + LAP + Tregs in CD4 + splenic T cells after 7 days of culturing. B and C, Graphs represent the average percentages of nTregs and CD4 + LAP + Tregs in CD4 + splenic T cells. D, Quantification of IFN‐γ ( # P =0.0578 vs no DCs; # P =0.8652 vs iDCs) and IL‐4 released by CD4 + T cells. E and F, Proliferative response of purified CD4 + ( # P =0.5676, * P =0.0163) or CD4 + CD25 + T cells exposed to different stimulus. G, Conversion of naive CD4 + CD25 − T cells into CD4 + CD25 + Foxp3 + T cells under different conditions (** P =0.0019; *** P =0.0003). Data are shown as the average±SD of 3 to 5 independent experiments. **** P <0.0001. APC indicates allophycocyanin; BM, bone marrow; DCs, dendritic cells; iDCs, immature DCs; FITC, fluorecein isothiocyanate; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; oxLDL, oxidized low‐density lipoprotein; PE, phycoerythrin; SD, standard deviation; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Coculture of BM‐DCs and T cells. A, Representative FACS analysis of the percentages of nTregs and CD4 + LAP + Tregs in CD4 + splenic T cells after 7 days of culturing. B and C, Graphs represent the average percentages of nTregs and CD4 + LAP + Tregs in CD4 + splenic T cells. D, Quantification of IFN‐γ ( # P =0.0578 vs no DCs; # P =0.8652 vs iDCs) and IL‐4 released by CD4 + T cells. E and F, Proliferative response of purified CD4 + ( # P =0.5676, * P =0.0163) or CD4 + CD25 + T cells exposed to different stimulus. G, Conversion of naive CD4 + CD25 − T cells into CD4 + CD25 + Foxp3 + T cells under different conditions (** P =0.0019; *** P =0.0003). Data are shown as the average±SD of 3 to 5 independent experiments. **** P <0.0001. APC indicates allophycocyanin; BM, bone marrow; DCs, dendritic cells; iDCs, immature DCs; FITC, fluorecein isothiocyanate; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; oxLDL, oxidized low‐density lipoprotein; PE, phycoerythrin; SD, standard deviation; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Purification, Standard Deviation

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Triglycerides Levels in All Groups

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques:

TSLP inhibits the development of atherosclerosis (Ι). A, Representative sections of aortic sinus stained with the Oil Red O and antibodies specific for MOMA‐2 for macrophages, Foxp3 for Tregs, α‐smooth muscle actin staining, and collagen staining in ApoE −/− mice in different groups (PBS and TSLP) at 16 weeks. Black bar=200 or 100 μm (Foxp3); black arrows indicate examples of Foxp3‐positive cells. B through F, Quantitative analysis of lesion size (*** P =0.0004), MOMA‐2 (*** P =0.0005), Foxp3 (** P =0.0066), α‐SMA ( # P =0.4424), and collagen ( # P =0.5900) staining in different groups (PBS and TSLP). Values are presented as mean±SD, n=7 to 9. MOMA indicates monocyte/macrophage; SD, standard deviation; SMA, smooth muscle actin; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: TSLP inhibits the development of atherosclerosis (Ι). A, Representative sections of aortic sinus stained with the Oil Red O and antibodies specific for MOMA‐2 for macrophages, Foxp3 for Tregs, α‐smooth muscle actin staining, and collagen staining in ApoE −/− mice in different groups (PBS and TSLP) at 16 weeks. Black bar=200 or 100 μm (Foxp3); black arrows indicate examples of Foxp3‐positive cells. B through F, Quantitative analysis of lesion size (*** P =0.0004), MOMA‐2 (*** P =0.0005), Foxp3 (** P =0.0066), α‐SMA ( # P =0.4424), and collagen ( # P =0.5900) staining in different groups (PBS and TSLP). Values are presented as mean±SD, n=7 to 9. MOMA indicates monocyte/macrophage; SD, standard deviation; SMA, smooth muscle actin; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Staining, Standard Deviation

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: HDL Cholesterol Levels in All Groups

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques:

TSLP inhibits the development of atherosclerosis (Π). A, Representative photographs of Oil Red O staining in the surface lesion area of the thoracic aorta. B, Representative sections of aortic sinus stained with antibodies specific for CD4 for T cells and CD11c for dendritic cells in ApoE −/− mice in different groups (PBS and TSLP) at 16 weeks. Black bar=100 μm; black arrows indicate examples of CD4‐positive cells. C through E, Quantitative analysis of the percent lesion area of total vessel area (* P =0.0104), number of CD4‐positive cells ( # P =0.0878), and percent of CD11c staining area ( # P =0.6022). Values are presented as the mean±SD, n=6. SD indicates standard deviation; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: TSLP inhibits the development of atherosclerosis (Π). A, Representative photographs of Oil Red O staining in the surface lesion area of the thoracic aorta. B, Representative sections of aortic sinus stained with antibodies specific for CD4 for T cells and CD11c for dendritic cells in ApoE −/− mice in different groups (PBS and TSLP) at 16 weeks. Black bar=100 μm; black arrows indicate examples of CD4‐positive cells. C through E, Quantitative analysis of the percent lesion area of total vessel area (* P =0.0104), number of CD4‐positive cells ( # P =0.0878), and percent of CD11c staining area ( # P =0.6022). Values are presented as the mean±SD, n=6. SD indicates standard deviation; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Staining, Standard Deviation

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Body Weight in All Groups

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques:

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Total Cholesterol Levels in All Groups

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques:

TSLP‐DCs attenuate the development of atherosclerosis (Ι). A, Representative sections of aortic sinus stained with Oil Red O and antibodies specific for MOMA‐2 for macrophages, Foxp3 for Tregs, α‐smooth muscle actin staining, and collagen staining in ApoE −/− mice in different groups (no DCs, iDCs, oxLDL‐DCs, and TSLP‐DCs) at 16 weeks. Black bar=200 or 100 μm (Foxp3); black arrows indicate examples Foxp3‐positive cells. B through F, Quantitative analysis of lesion size (** P =0.0074 vs oxLDL‐DCs; ** P =0.0047 vs TSLP‐DCs), MOMA‐2 ( # P =0.6304; * P =0.0391), Foxp3 (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0158), α‐SMA ( # P =0.9994 vs TSLP‐DCs; # P =0.9647 vs oxLDL‐DCs), and collagen ( # P =0.9878 vs TSLP‐DCs; # P =0.9878 vs oxLDL‐DCs) staining in different groups. Values are presented as the mean±SD, n=7 to 9. DCs indicates dendritic cells; iDCs, immature DCs; MOMA, monocyte/macrophage; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; SMA, smooth muscle actin; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: TSLP‐DCs attenuate the development of atherosclerosis (Ι). A, Representative sections of aortic sinus stained with Oil Red O and antibodies specific for MOMA‐2 for macrophages, Foxp3 for Tregs, α‐smooth muscle actin staining, and collagen staining in ApoE −/− mice in different groups (no DCs, iDCs, oxLDL‐DCs, and TSLP‐DCs) at 16 weeks. Black bar=200 or 100 μm (Foxp3); black arrows indicate examples Foxp3‐positive cells. B through F, Quantitative analysis of lesion size (** P =0.0074 vs oxLDL‐DCs; ** P =0.0047 vs TSLP‐DCs), MOMA‐2 ( # P =0.6304; * P =0.0391), Foxp3 (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0158), α‐SMA ( # P =0.9994 vs TSLP‐DCs; # P =0.9647 vs oxLDL‐DCs), and collagen ( # P =0.9878 vs TSLP‐DCs; # P =0.9878 vs oxLDL‐DCs) staining in different groups. Values are presented as the mean±SD, n=7 to 9. DCs indicates dendritic cells; iDCs, immature DCs; MOMA, monocyte/macrophage; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; SMA, smooth muscle actin; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Staining, Standard Deviation

TSLP‐DCs attenuate the development of atherosclerosis (Π). A through C, Quantitative analysis of the percent lesion area of total vessel area (* P =0.0270), number of CD4‐positive cells ( # P =0.7448), and percent of CD11c staining area ( # P =0.9998) in different groups (no DCs, iDCs, oxLDL‐DCs, and TSLP‐DCs) at 16 weeks. Values are presented as the mean±SD, n=5 to 6. DCs indicates dendritic cells; iDCs, immature DCs; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: TSLP‐DCs attenuate the development of atherosclerosis (Π). A through C, Quantitative analysis of the percent lesion area of total vessel area (* P =0.0270), number of CD4‐positive cells ( # P =0.7448), and percent of CD11c staining area ( # P =0.9998) in different groups (no DCs, iDCs, oxLDL‐DCs, and TSLP‐DCs) at 16 weeks. Values are presented as the mean±SD, n=5 to 6. DCs indicates dendritic cells; iDCs, immature DCs; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Staining, Standard Deviation

Effects of TSLP administration on nTregs, CD4 + LAP + Tregs, and Th1, Th2, and Th17 cells in spleens in ApoE −/− mice on days 14. A, CD4 + T‐cell subsets were gated (a). Representative pictures of nTregs (b), CD4 + LAP + Tregs (c), Th1 (d), Th2 (e), and Th17 (f) are shown. Numbers in upper right quadrants indicate percentages of these cells. B, Results of statistical analysis of average percentages of nTregs (** P =0.0046) and Th1 cells in different groups (PBS and TSLP). C, Results of statistical analysis of average percentages of CD4 + LAP + Tregs (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022), and Th2 and Th17 cells ( # P =0.5786) in different groups (PBS and TSLP). Six mice were analyzed for each group. Values are presented as the mean±SD. **** P <0.0001. APC indicates allophycocyanin; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; SD, standard deviation; SSC, side scatter; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Effects of TSLP administration on nTregs, CD4 + LAP + Tregs, and Th1, Th2, and Th17 cells in spleens in ApoE −/− mice on days 14. A, CD4 + T‐cell subsets were gated (a). Representative pictures of nTregs (b), CD4 + LAP + Tregs (c), Th1 (d), Th2 (e), and Th17 (f) are shown. Numbers in upper right quadrants indicate percentages of these cells. B, Results of statistical analysis of average percentages of nTregs (** P =0.0046) and Th1 cells in different groups (PBS and TSLP). C, Results of statistical analysis of average percentages of CD4 + LAP + Tregs (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022), and Th2 and Th17 cells ( # P =0.5786) in different groups (PBS and TSLP). Six mice were analyzed for each group. Values are presented as the mean±SD. **** P <0.0001. APC indicates allophycocyanin; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; SD, standard deviation; SSC, side scatter; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: MANN-WHITNEY, Standard Deviation

Effects of TSLP‐DC administration on nTregs, CD4 + LAP + Tregs, and Th1, Th2, and Th17 cells in spleens in ApoE −/− mice on day 14. A, CD4 + T‐cell subsets were gated (a). Representative pictures of nTregs (b), CD4 + LAP + Tregs (c), Th1 (d), Th2 (e), and Th17 (f) are shown. Numbers in upper right quadrants indicate percentages of these cells. B, Results of statistical analysis of average percentages of nTregs (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0374 vs no DCs; # P =0.2596 vs iDCs; * P =0.0162 vs oxLDL‐DCs) and Th1 cells (** P =0.0058; *** P =0.0007) in different groups. C, Results of statistical analysis of average percentages of CD4 + LAP + Tregs (** P =0.0010 vs no DCs; ** P =0.0012 vs iDCs; *** P =0.0008), Th2 (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.9999; * P =0.0226; ** P =0.0066), and Th17 cells ( # P =0.9726) in different groups. Six mice were analyzed for each group. Values are presented as the mean±SD. **** P <0.0001. APC indicates allophycocyanin; DCs, dendritic cells; iDCs, immature DCs; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Effects of TSLP‐DC administration on nTregs, CD4 + LAP + Tregs, and Th1, Th2, and Th17 cells in spleens in ApoE −/− mice on day 14. A, CD4 + T‐cell subsets were gated (a). Representative pictures of nTregs (b), CD4 + LAP + Tregs (c), Th1 (d), Th2 (e), and Th17 (f) are shown. Numbers in upper right quadrants indicate percentages of these cells. B, Results of statistical analysis of average percentages of nTregs (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0374 vs no DCs; # P =0.2596 vs iDCs; * P =0.0162 vs oxLDL‐DCs) and Th1 cells (** P =0.0058; *** P =0.0007) in different groups. C, Results of statistical analysis of average percentages of CD4 + LAP + Tregs (** P =0.0010 vs no DCs; ** P =0.0012 vs iDCs; *** P =0.0008), Th2 (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.9999; * P =0.0226; ** P =0.0066), and Th17 cells ( # P =0.9726) in different groups. Six mice were analyzed for each group. Values are presented as the mean±SD. **** P <0.0001. APC indicates allophycocyanin; DCs, dendritic cells; iDCs, immature DCs; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Standard Deviation

Expression of mRNA and levels of cytokines and antibodies in vivo. A and B, Levels of plasma IFN‐γ (*** P =0.0002), IL‐4 (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022), IL‐12 ( # P =0.3061), and TGF‐β (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022) in PBS and TSLP groups. C and D, Levels of plasma IFN‐γ (* P =0.0231; ** P =0.0035), IL‐4 (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.0506), IL‐12 ( # P =0.6422; * P =0.0217), and TGF‐β (median with 25th and 75th percentiles; Kruskal–Wallis test,;** P =0.0049) in the groups no DCs, iDC, oxLDL‐DCs, and TSLP‐DCs. E, Expression of IFN‐γ, Foxp3, TGF‐β, IL‐4 (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022), IL‐10 (*** P =0.0001), and IL‐12 ( # P =0.0513) mRNA in aorta in PBS and TSLP groups. F, Expression of IFN‐γ, Foxp3, TGF‐β (*** P =0.0002), IL‐4, IL‐10 (** P =0.0061), and IL‐12 ( # P =0.1682) mRNA in spleen in different groups. G, Graphs represent expression of IFN‐γ (** P =0.0012), Foxp3 (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0301), TGF‐β (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0235), IL‐4 (*** P =0.0004), IL‐10 (** P =0.0047), and IL‐12 ( # P =0.5352; *** P =0.0005) mRNA in spleens of different groups. H, Graphs represent expression of IFN‐γ (* P =0.0171), Foxp3, TGF‐β (** P =0.0045), IL‐4, IL‐10 (*** P =0.0003), and IL‐12 ( # P =0.0554) mRNA and in aorta. I, Levels of plasma IgM (median with 25th and 75th percentiles; Mann–Whitney rank sum test; * P =0.0286), IgG 1 , and IgG 2a (* P =0.0282). Six mice were analyzed for each group. Values are presented as the mean±SD. **** P <0.0001. DCs indicates dendritic cells; iDCs, immature DCs; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; OD, optical density; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; TGF‐β, transforming growth factor‐β; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Expression of mRNA and levels of cytokines and antibodies in vivo. A and B, Levels of plasma IFN‐γ (*** P =0.0002), IL‐4 (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022), IL‐12 ( # P =0.3061), and TGF‐β (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022) in PBS and TSLP groups. C and D, Levels of plasma IFN‐γ (* P =0.0231; ** P =0.0035), IL‐4 (median with 25th and 75th percentiles; Kruskal–Wallis test; # P =0.0506), IL‐12 ( # P =0.6422; * P =0.0217), and TGF‐β (median with 25th and 75th percentiles; Kruskal–Wallis test,;** P =0.0049) in the groups no DCs, iDC, oxLDL‐DCs, and TSLP‐DCs. E, Expression of IFN‐γ, Foxp3, TGF‐β, IL‐4 (median with 25th and 75th percentiles; Mann–Whitney rank sum test; ** P =0.0022), IL‐10 (*** P =0.0001), and IL‐12 ( # P =0.0513) mRNA in aorta in PBS and TSLP groups. F, Expression of IFN‐γ, Foxp3, TGF‐β (*** P =0.0002), IL‐4, IL‐10 (** P =0.0061), and IL‐12 ( # P =0.1682) mRNA in spleen in different groups. G, Graphs represent expression of IFN‐γ (** P =0.0012), Foxp3 (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0301), TGF‐β (median with 25th and 75th percentiles; Kruskal–Wallis test; * P =0.0235), IL‐4 (*** P =0.0004), IL‐10 (** P =0.0047), and IL‐12 ( # P =0.5352; *** P =0.0005) mRNA in spleens of different groups. H, Graphs represent expression of IFN‐γ (* P =0.0171), Foxp3, TGF‐β (** P =0.0045), IL‐4, IL‐10 (*** P =0.0003), and IL‐12 ( # P =0.0554) mRNA and in aorta. I, Levels of plasma IgM (median with 25th and 75th percentiles; Mann–Whitney rank sum test; * P =0.0286), IgG 1 , and IgG 2a (* P =0.0282). Six mice were analyzed for each group. Values are presented as the mean±SD. **** P <0.0001. DCs indicates dendritic cells; iDCs, immature DCs; IFN, interferon; IL, interleukin; LAP, latency‐associated peptide; OD, optical density; oxLDL, oxidized low‐density lipoprotein; SD, standard deviation; TGF‐β, transforming growth factor‐β; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Expressing, In Vivo, Clinical Proteomics, MANN-WHITNEY, Standard Deviation

Neutralization of TGF‐β in vivo abrogates the effect of TSLP on atherosclerosis. A, Representative sections of aortic sinus stained with Oil Red O and antibodies specific for MOMA‐2 for macrophages and α‐smooth muscle actin staining in ApoE −/− mice at 16 weeks. Black bar=200 μm. B through D, Quantitative analysis of lesion size (** P =0.0018), MOMA‐2 (** P =0.0023), and α‐SMA staining ( # P =0.9962). Values are presented as the mean±SD, n=7 to 9. MOMA indicates monocyte/macrophage; SD, standard deviation; SMA, smooth muscle actin; TGF‐β, transforming growth factor–β; TSLP, thymic stromal lymphopoietin.

Journal: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Article Title: Thymic Stromal Lymphopoietin Attenuates the Development of Atherosclerosis in ApoE −/− Mice

doi: 10.1161/JAHA.113.000391

Figure Lengend Snippet: Neutralization of TGF‐β in vivo abrogates the effect of TSLP on atherosclerosis. A, Representative sections of aortic sinus stained with Oil Red O and antibodies specific for MOMA‐2 for macrophages and α‐smooth muscle actin staining in ApoE −/− mice at 16 weeks. Black bar=200 μm. B through D, Quantitative analysis of lesion size (** P =0.0018), MOMA‐2 (** P =0.0023), and α‐SMA staining ( # P =0.9962). Values are presented as the mean±SD, n=7 to 9. MOMA indicates monocyte/macrophage; SD, standard deviation; SMA, smooth muscle actin; TGF‐β, transforming growth factor–β; TSLP, thymic stromal lymphopoietin.

Article Snippet: Recombinant mouse TSLP (lot no. ELR0511061), anti‐TSLP‐biotin antibody (cat no. BAF555), and anti‐LAP‐PE antibody (lot no. AACP0809111) were from R&D Systems.

Techniques: Neutralization, In Vivo, Staining, Standard Deviation

Review

anti tslp (R&D Systems)

Structured Review

Images

Related Articles

Incubation:

Recombinant:

Similar Products

Image Search Results